
PSTV Stock Forecast & Price Target
PSTV Analyst Ratings
Bulls say
Plus Therapeutics Inc. is advancing its key treatment candidate, rhenium (186Re) obisbemeda, aimed at addressing significant unmet needs in central nervous system cancers, particularly recurrent glioblastoma and leptomeningeal metastases. The favorable reception from the FDA regarding an accelerated approval pathway for Reyobiq, along with the completion of a productive Type B meeting to define pivotal trial strategies, underscores the therapy's potential efficacy and market relevance. Additionally, the recent successful public offering generating approximately $15 million enhances the company's financial position, supporting operational flexibility and manufacturing scalability as it prepares for future clinical trials.
Bears say
The financial outlook for Plus Therapeutics, Inc. appears muted, primarily due to a significant reduction in the 12-month price target from $2.00 to $1.00 per diluted share, following a recent equity offering and potential future dilution from warrant exercises. Additionally, the company's clinical programs targeting recurrent glioblastoma and leptomeningeal metastases face considerable uncertainty, as previous studies have reported median overall survival (OS) rates that vary widely, which may hinder investor confidence. This variability in clinical outcomes, combined with financial dilution concerns, contributes to a negative outlook on the stock.
This aggregate rating is based on analysts' research of Plus Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
PSTV Analyst Forecast & Price Prediction
Start investing in PSTV
Order type
Buy in
Order amount
Est. shares
0 shares